Jimmy Fund Radio-Telethon happening now! Come help support patients like John to beat cancer. It's such a privilege to be part of John's team and thank you John for sharing your story! #KCANCER The Jimmy Fund Dana-Farber Lank Center for Genitourinary Oncology Susan danafarber.jimmyfund.org/site/TR?fr_id=…

1/ 🚨 Just in European Urology , our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma. Effort co-led with Talal El Zarif, MD, with amazing mentorship from Daniel Heng Toni Choueiri, MD sciencedirect.com/science/articl… Dana-Farber Lank Center for Genitourinary Oncology Yale School of Medicine OncoAlert

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

2/ Alterations in VHL are seen in >90% of ccRCC ➡️VHL negatively regulates the HIF pathway (The Nobel Prize 2019 KaelinLab) ➡️ targeting HIF2a w/ belzutifan (MK-6482) showed promising results in early trial, published Nature Medicine: nature.com/articles/s4159… Review of this story

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following ProstatectomyA Nonrandomized Controlled Trial jamanetwork.com/journals/jamao… This phase 2, single-arm trial evaluated the efficacy of olaparib, a poly(ADP-ribose) polymerase

GU Research Digest for the week of August 17 - 23: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

“If we can identify neoantigens specific to a patient’s tumor, we can make a personalized vaccine to target those tumor-specific antigens,” says David Braun, MD, PhD, a Dana-Farber oncologist leading a trial of a neoantigen-based vaccine for kidney cancer. ms.spr.ly/6016lv4Oj

From JAMA: Renal cell carcinoma (RCC) is a common cancer, with an estimated 434 840 incident cases worldwide in 2022. This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of RCC. ja.ma/3AGlJrL

💫🌟📢 The future of oncology care is here! 🚀🌟💫 Cristiane D Bergerot Mazie Tsang, MD, MAS, MS Ramy Sedhom, MD OncoAlert 🔹 Telehealth and ePROs enhance treatment accessibility and quality. 🔹 Empower patients in their treatment journey. 🔹 Reduce care disparities and increase patient

🩸🧬Liquid biopsy is transforming cancer detection and monitoring, offering noninvasive insights. Recent studies show that ctDNA levels correlate with outcomes in RCC. Could emerging technologies enhance this? Marc Machaalani Karl Semaan, MD, MSc Marc Eid Rashad Nawfal, MD Razane El Hajj Chehade

GU Research Digest for the week of August 24 - 30: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

BC Football kicks off tonight & No matter how we finish this year -THE most important win has happened. My friend & fellow Dana-Farber patient Bryce Steele is back. So proud of Bryce and how he continues to DEFY cancer. #2 is Coming!! 👊👊 Go 🦅🦅 Boston College Football The Jimmy Fund

On Labor Day, revisit Toni Morrison’s reflections on the job advice she received from her father. newyorkermag.visitlink.me/xM8lFc

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

WE. ARE. BC. 🦅

Dr. Laurie Glimcher, CEO of Dana-Farber Cancer Institute, said she would step down next month. Dr. Benjamin Ebert, chair of Dana-Farber’s medical oncology department, will take over on Oct. 1. trib.al/WVBqnUH

🚀 Excited to share that I’ve joined Emory School of Medicine & Winship Cancer Institute of Emory University to launch The Berchuck Lab. Our research is focused on using liquid biopsy to improve outcomes for people living with cancer. We’re hiring for several key roles! Learn more & apply: theberchucklab.org

Thank you TIME for highlighting our work in Kidney Cancer at Dana-Farber and Dana-Farber Lank Center for Genitourinary Oncology time.com/7018184/kidney…

Tumor dynamics in patients treated with anti-PD-1 monotherapy beyond progression (TBP) 👉 cell.com/cancer-cell/fu… (Cancer Cell) 🗝 Key findings: #Melanoma: ORR 8.6% #NSCLC: ORR 2.8% #GastricCancer: ORR 3.4% #HNSCC: ORR 3.6% #RCC: ORR 7.8% Urothelial Carcinoma: ORR 6.2%

My TOP 10 #GU ESMO - Eur. Oncology abstracts for #ESMO24 1/ 3